- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01378312
A Study to Evaluate Safety and Immunogenicity of AERAS-402
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
This Phase I study will be conducted as a randomized, double-blind, placebo-controlled study in healthy adult subjects who are HIV-negative, BCG-vaccinated, and have no evidence of tuberculosis infection. The study will be conducted at one clinical research site in India.
The available live tuberculosis vaccine, Bacillus Calmette-Guérin (BCG), provides incomplete protection against pulmonary tuberculosis. For unknown reasons, a BCG revaccination or "booster", while not toxic, does not provide much additional protection. AERAS-402 presents tuberculosis antigens in the setting of a new, live, replication-deficient adenovirus vaccine that may increase T cell-mediated immunity and thus protection from tuberculosis. Since BCG-vaccinated individuals are the population for which AERAS-402 might be indicated, AERAS-402 will be administered to individuals already vaccinated with BCG.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bangalore, India
- Lotus Labs
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is male or female
- Is age 18 through 45 years on Study Day 0
- Has completed written informed consent
- Had BCG vaccination at least 5 years ago, documented through medical history or presence of scar
- Has general good health, confirmed by medical history and physical examination
- Has Body Mass Index (BMI) between 19 and 30 (kg/m2)
- Has ability to complete follow-up period of 182 days as required by the protocol
- Females: Ability to avoid pregnancy from 28-days prior to initial study vaccination through the duration of their participation in the study.
- Will commit to avoiding elective surgery for the duration of the study
- Has ability to stay in contact with the investigative site for the duration of the study
- Has completed simultaneous enrollment in Aeras Vaccine Development Registry protocol
Exclusion Criteria:
- Acute illness on the day of randomization
- Oral temperature ≥37.5°C on the day of randomization
- Evidence of significant active infection
- Used immunosuppressive medication within 42 days before entry into the study
- Received immunoglobulin or blood products within 42 days
- Received any investigational drug therapy or vaccine within 182 days
- Received any standard vaccine within 42 days
- Participated in any clinical trial of an investigational adenovirus-based vaccine previously.
- Current chronic drug therapy
- History or laboratory evidence of any past, present or future possible immunodeficiency state which will include (but is not limited to) any laboratory indication of HIV infection
- History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine
- Previous medical history that may compromise the safety of the subject in the study
- Evidence of a new acute illness that may compromise the safety of the subject in the study
- Evidence of chronic hepatitis (e.g., hepatitis B core antibody, or hepatitis C antibody, or other)
- Inability to discontinue daily medications except contraceptives during the study period
- History of alcohol or drug abuse within the past 2 years
- Tobacco or cannabis smoking three or more days per week
- Positive urine test for illicit drugs (opiates, cocaine, amphetamines)
- History or evidence of any systemic disease on physical examination
- History or evidence (including chest X-ray) of active tuberculosis
- Shared a residence within the last year with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
- All females: Positive urine pregnancy test during screening; positive serum pregnancy test on the day of study vaccination; are nursing
- Abnormal (per local laboratory parameters) hemoglobin, hematocrit, white blood cell count, absolute neutrophil count, absolute lymphocyte count, prothrombin time (PT), partial thromboplastin time (PTT), serum creatinine, GGT, ALT, AST, total bilirubin, alkaline phosphatase (ALP), or creatinine drawn within 36 hours prior to randomization.
- Laboratory test evidence of Mtb infection
- Tuberculin skin test evidence of Mtb infection, defined as 15 mm of induration or greater.
- Anal intercourse with another man at least one time (with or without condoms)
- Exchange of goods, money, services or drugs for sex.
- Use of intravenous drugs.
- Sexual intercourse or genital contact within the last 12 months with a known HIV positive individual
- Vaginal intercourse within the last 12 months without use of a condom with a known user of intravenous drugs
- Oral to genital contact within the last 12 months with a known user of intravenous drug
- Vaginal intercourse within the last 12 months without use of a condom with an individual known to have more than one sex partner
- Oral to genital contact within the last 12 months with an individual known to have more than one sex partner
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Arm
|
0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
|
Active Comparator: AERAS 402 Arm
|
0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number and Percentage of Adverse Events by treatment group
Time Frame: Day 56
|
The number and percentage of Adverse Events will be presented and compared by treatment group (placebo vs AERAS 402).
|
Day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune Response
Time Frame: Day 182
|
Percentage of CD4 and CD8 cells producing specific cytokines will be measured and tabulated in subjects who have received the vaccine.
|
Day 182
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vanya Dhagat, MD, Lotus Labs
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-004-402
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States